GET DAILY SIGNALSProQR Therapeutics (PRQR) Q3 2026 Earnings Outlook: Pipeline Progress in View
Key Takeaways
- Consensus estimates point to a net loss of roughly $0.11 per share for ProQR Therapeutics (PRQR) in the third quarter of 2026.
- Revenue expectations are modest and generally clustered in a range of about $4 million to $5 million, reflecting the company's early-stage profile.
- The prior quarter (Q2 2026) delivered an earnings and revenue beat, offering a backdrop of improving execution heading into this report.
- Investor focus will center on the Axiomer RNA-editing platform and the AX-0810 program rather than headline financials alone.
- Cash runway and research and development (R&D) spending trends remain key signals for a pre-commercial-stage biotech.
Why This Earnings Report Matters
ProQR Therapeutics N.V. is a Netherlands-based biotechnology company focused on RNA therapeutics, primarily through its Axiomer RNA-editing platform and the AX-0810 program targeting cholestatic diseases. Because the company has not yet reached commercial scale, its quarterly financials largely reflect R&D costs, grant or collaboration income, and cash burn rather than product sales. As a result, this earnings report matters less for revenue momentum and more for the signals management provides about pipeline progress, clinical timelines, and capital runway. With the stock trading at a modest market capitalization relative to its development ambitions, investors watch these updates closely for signs of execution and near-term catalysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Are Expected to Show
For the third quarter of fiscal 2026 (the quarter ended September 30, 2026), consensus estimates point to a net loss of approximately $0.11 per share. Revenue expectations vary across the sell-side, with estimates generally falling in a range of roughly $4 million to $5 million — modest figures that underscore the company's early-stage nature.
Recent history offers useful context. In the second quarter of 2026, reported in August 2026, ProQR posted a narrower-than-expected loss and revenue that exceeded consensus, with earnings per share of about -$0.09 versus expectations of roughly -$0.14. In the year-ago quarter (Q3 2025), the company reported a loss in the range of approximately $0.10 to $0.12 per share on revenue in the low-single-digit millions.
Key metrics to watch include research and development (R&D) expense, general and administrative expense, cash and equivalents, and any commentary on the Axiomer platform and AX-0810 program. From what I see, the AI Daily Buy/Sell Signals tool provided additional perspective on recent trading patterns around similar names.
Market Sentiment Heading Into the Report
Heading into the report, sentiment around PRQR is shaped more by pipeline expectations than by quarterly figures. As a small-cap, clinical-stage biotech, the stock tends to exhibit elevated volatility around earnings and data announcements, with investors reacting sharply to any updates on the Axiomer platform and AX-0810 program. The prior quarter's beat provided a modest positive backdrop, but the market has historically shown a mixed reaction to results. Key risk factors include slower-than-expected clinical progress, higher R&D spending, and any dilution associated with financing activity. Investors will be watching whether management can reinforce confidence in its development roadmap and capital position.
What to Watch After the Release
Following the third-quarter report, the primary question for investors will be whether management provides clarity on the Axiomer RNA-editing platform and the AX-0810 cholestatic disease program. The Axiomer approach relies on the body's own ADAR (adenosine deaminase acting on RNA) enzymes to make precise edits in RNA, and any update on preclinical or clinical advancement could serve as a meaningful catalyst.
Cash runway remains a central concern for a company still in the investment phase. Investors should track R&D expense trends, cash and equivalents on the balance sheet, and any guidance on how long existing capital is expected to fund operations. A widening or narrowing of the quarterly loss can signal whether the company is scaling its programs efficiently.
Broader industry dynamics also matter. The RNA-editing and RNA-therapeutics space is competitive, and sentiment can shift with funding conditions for development-stage biotech companies. While no single quarter will define the company's trajectory, the combination of pipeline updates, spending discipline, and balance-sheet strength will shape how investors interpret the path ahead. I’m watching this closely for any new details on the platform.
Using AI Tools in Biotech Research
In my own process, I often turn to Tickeron’s AI Screener when evaluating early-stage names like this one. It allows quick filtering by fundamentals, technical patterns, and industry trends, which helps put quarterly expectations in a broader context without replacing deeper fundamental work. The tool has become a regular part of how I cross-check ideas before earnings season.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for PRQR turns positive, indicating new upward trend
PRQR saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned positive. In 83 of the 97 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRQR's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for PRQR just turned positive on October 28, 2026. Looking at past instances where PRQR's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Following a +6.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 173 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 59 cases where PRQR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PRQR entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.504) is normal, around the industry mean (2.904). P/E Ratio (-3.525) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders
Industry Biotechnology
Advertisement